Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician's perspective

Ken Herrmann, Johannes Czernin, Edward M. Wolin, Pawan Gupta, Martin Barrio, Antonio Gutierrez, Christiaan Schiepers, Sherly Mosessian, Michael E. Phelps, Martin S. Allen-Auerbach

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.

Methods: A set of 2 questionnaires (pre- PET and post-PET) was sent to the referring physicians of 100 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE. Questionnaires on 88 patients were returned (response rate, 88%). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for metastatic disease was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated.

Results: The indications for PET/CT were initial and subsequent treatment strategy assessments in 14% and 86% of patients, respectively. Referring physicians reported that DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24%; increased and decreased suspicion in 9 [10%] and 12 [14%] patients, respectively). Intended management changes were reported in 53 of 88 (60%) patients. Twenty patients (23%) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7%) were switched from watch-and-wait to other treatment strategies. Conversely, 5 patients (6%) were switched from their initial treatment strategy to watch-and-wait.

Conclusion: This survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neuroendocrine tumors.

Original languageEnglish (US)
Pages (from-to)70-75
Number of pages6
JournalJournal of Nuclear Medicine
Volume56
Issue number1
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Neuroendocrine Tumors
Physicians
68Ga-DOTATATE
Drug Therapy
Somatostatin Receptors
Therapeutics

Keywords

  • DOTATATE
  • NET
  • Neuroendocrine tumors
  • PET
  • Somatostatin receptor

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Medicine(all)

Cite this

Herrmann, K., Czernin, J., Wolin, E. M., Gupta, P., Barrio, M., Gutierrez, A., ... Allen-Auerbach, M. S. (2015). Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician's perspective. Journal of Nuclear Medicine, 56(1), 70-75. https://doi.org/10.2967/jnumed.114.148247

Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors : The referring physician's perspective. / Herrmann, Ken; Czernin, Johannes; Wolin, Edward M.; Gupta, Pawan; Barrio, Martin; Gutierrez, Antonio; Schiepers, Christiaan; Mosessian, Sherly; Phelps, Michael E.; Allen-Auerbach, Martin S.

In: Journal of Nuclear Medicine, Vol. 56, No. 1, 01.01.2015, p. 70-75.

Research output: Contribution to journalReview article

Herrmann, K, Czernin, J, Wolin, EM, Gupta, P, Barrio, M, Gutierrez, A, Schiepers, C, Mosessian, S, Phelps, ME & Allen-Auerbach, MS 2015, 'Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician's perspective', Journal of Nuclear Medicine, vol. 56, no. 1, pp. 70-75. https://doi.org/10.2967/jnumed.114.148247
Herrmann, Ken ; Czernin, Johannes ; Wolin, Edward M. ; Gupta, Pawan ; Barrio, Martin ; Gutierrez, Antonio ; Schiepers, Christiaan ; Mosessian, Sherly ; Phelps, Michael E. ; Allen-Auerbach, Martin S. / Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors : The referring physician's perspective. In: Journal of Nuclear Medicine. 2015 ; Vol. 56, No. 1. pp. 70-75.
@article{3fe139e6e4e44c3590151c85deec2af6,
title = "Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician's perspective",
abstract = "Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.Methods: A set of 2 questionnaires (pre- PET and post-PET) was sent to the referring physicians of 100 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE. Questionnaires on 88 patients were returned (response rate, 88{\%}). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for metastatic disease was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated.Results: The indications for PET/CT were initial and subsequent treatment strategy assessments in 14{\%} and 86{\%} of patients, respectively. Referring physicians reported that DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24{\%}; increased and decreased suspicion in 9 [10{\%}] and 12 [14{\%}] patients, respectively). Intended management changes were reported in 53 of 88 (60{\%}) patients. Twenty patients (23{\%}) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7{\%}) were switched from watch-and-wait to other treatment strategies. Conversely, 5 patients (6{\%}) were switched from their initial treatment strategy to watch-and-wait.Conclusion: This survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neuroendocrine tumors.",
keywords = "DOTATATE, NET, Neuroendocrine tumors, PET, Somatostatin receptor",
author = "Ken Herrmann and Johannes Czernin and Wolin, {Edward M.} and Pawan Gupta and Martin Barrio and Antonio Gutierrez and Christiaan Schiepers and Sherly Mosessian and Phelps, {Michael E.} and Allen-Auerbach, {Martin S.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2967/jnumed.114.148247",
language = "English (US)",
volume = "56",
pages = "70--75",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "1",

}

TY - JOUR

T1 - Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors

T2 - The referring physician's perspective

AU - Herrmann, Ken

AU - Czernin, Johannes

AU - Wolin, Edward M.

AU - Gupta, Pawan

AU - Barrio, Martin

AU - Gutierrez, Antonio

AU - Schiepers, Christiaan

AU - Mosessian, Sherly

AU - Phelps, Michael E.

AU - Allen-Auerbach, Martin S.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.Methods: A set of 2 questionnaires (pre- PET and post-PET) was sent to the referring physicians of 100 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE. Questionnaires on 88 patients were returned (response rate, 88%). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for metastatic disease was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated.Results: The indications for PET/CT were initial and subsequent treatment strategy assessments in 14% and 86% of patients, respectively. Referring physicians reported that DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24%; increased and decreased suspicion in 9 [10%] and 12 [14%] patients, respectively). Intended management changes were reported in 53 of 88 (60%) patients. Twenty patients (23%) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7%) were switched from watch-and-wait to other treatment strategies. Conversely, 5 patients (6%) were switched from their initial treatment strategy to watch-and-wait.Conclusion: This survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neuroendocrine tumors.

AB - Somatostatin receptor imaging with 68Ga-DOTATATE PET/CT (DOTATATE) is increasingly used for managing patients with neuroendocrine tumors. The objective of this study was to determine referring physicians' perspectives on the impact of DOTATATE on the management of neuroendocrine tumors.Methods: A set of 2 questionnaires (pre- PET and post-PET) was sent to the referring physicians of 100 consecutive patients with known or suspected neuroendocrine tumors, who were evaluated with DOTATATE. Questionnaires on 88 patients were returned (response rate, 88%). Referring physicians categorized the DOTATATE findings on the basis of the written PET reports as negative, positive, or equivocal for disease. The likelihood for metastatic disease was scored as low, moderate, or high. The intended management before and changes as a consequence of the PET study were indicated.Results: The indications for PET/CT were initial and subsequent treatment strategy assessments in 14% and 86% of patients, respectively. Referring physicians reported that DOTATATE led to a change in suspicion for metastatic disease in 21 patients (24%; increased and decreased suspicion in 9 [10%] and 12 [14%] patients, respectively). Intended management changes were reported in 53 of 88 (60%) patients. Twenty patients (23%) scheduled to undergo chemotherapy were switched to treatments without chemotherapy, and 6 (7%) were switched from watch-and-wait to other treatment strategies. Conversely, 5 patients (6%) were switched from their initial treatment strategy to watch-and-wait.Conclusion: This survey of referring physicians demonstrates a substantial impact of DOTATATE on the intended management of patients with neuroendocrine tumors.

KW - DOTATATE

KW - NET

KW - Neuroendocrine tumors

KW - PET

KW - Somatostatin receptor

UR - http://www.scopus.com/inward/record.url?scp=84920461678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920461678&partnerID=8YFLogxK

U2 - 10.2967/jnumed.114.148247

DO - 10.2967/jnumed.114.148247

M3 - Review article

C2 - 25500825

AN - SCOPUS:84920461678

VL - 56

SP - 70

EP - 75

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 1

ER -